A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The study is designed to test the safety, tolerability of a newly developed form of
ketoconazole (DIO-902) for the treatment of elevated blood sugars in type 2 diabetes. This
study also will also examine the effect of the drug on total and LDL cholesterol and blood
pressure. Elevated cortisol may contribute to the development of Type II diabetes. The
investigational drug DIO-902 may reduce the level of cortisol in blood and therefore provide
better control of blood sugar levels in patients with Type II diabetes.